Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM).

IF 1.6 4区医学 Q4 ENDOCRINOLOGY & METABOLISM Archives of Endocrinology Metabolism Pub Date : 2024-11-25 eCollection Date: 2024-01-01 DOI:10.20945/2359-4292-2024-0422

Rodrigo O Moreira, Cynthia M Valerio, Alexandre Hohl, Cristiane Moulin, Fábio Moura, Fábio R Trujilho, Fernando Gerchman, Livia L Correa, Marcio C Mancini, Maria Edna Melo, Rodrigo N Lamounier, Simone van de Sande-Lee, Thaísa D G Trujilho, Paulo A C Miranda, Bruno Halpern

{"title":"Pharmacologic Treatment of Obesity in adults and its impact on comorbidities: 2024 Update and Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM).","authors":"Rodrigo O Moreira, Cynthia M Valerio, Alexandre Hohl, Cristiane Moulin, Fábio Moura, Fábio R Trujilho, Fernando Gerchman, Livia L Correa, Marcio C Mancini, Maria Edna Melo, Rodrigo N Lamounier, Simone van de Sande-Lee, Thaísa D G Trujilho, Paulo A C Miranda, Bruno Halpern","doi":"10.20945/2359-4292-2024-0422","DOIUrl":null,"url":null,"abstract":"<p><p>Pharmacological treatment of obesity is passing through many changes in the last decades; different agents have been approved, and newer options are leaning towards higher efficacy and a more favourable safety profile; however, medications approved for a longer time are still available and useful for many patients. This document is an 2024 Update Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM), with the aim of reviewing all the approved medications for the management of obesity in Brazil (sibutramine, orlistat, liraglutide, semaglutide and bupropion/naltrexone fixed dose), with the addition of tirzepatide, that is approved in other countries and likely approved soon in Brazil. The review is focused on efficacy, safety profile and the impact of drugs (based on existing studies) on different comorbidities.</p>","PeriodicalId":54303,"journal":{"name":"Archives of Endocrinology Metabolism","volume":"68 ","pages":"e240422"},"PeriodicalIF":1.6000,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11634287/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Archives of Endocrinology Metabolism","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.20945/2359-4292-2024-0422","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q4","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}

引用次数: 0

Abstract

Pharmacological treatment of obesity is passing through many changes in the last decades; different agents have been approved, and newer options are leaning towards higher efficacy and a more favourable safety profile; however, medications approved for a longer time are still available and useful for many patients. This document is an 2024 Update Position Statement of Specialists from the Brazilian Association for the Study of Obesity and Metabolic Syndrome (Abeso) and the Brazilian Society of Endocrinology and Metabolism (SBEM), with the aim of reviewing all the approved medications for the management of obesity in Brazil (sibutramine, orlistat, liraglutide, semaglutide and bupropion/naltrexone fixed dose), with the addition of tirzepatide, that is approved in other countries and likely approved soon in Brazil. The review is focused on efficacy, safety profile and the impact of drugs (based on existing studies) on different comorbidities.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

成人肥胖的药物治疗及其对合并症的影响：巴西肥胖与代谢综合征研究协会（Abeso）和巴西内分泌与代谢学会（SBEM）专家的2024年更新和立场声明。

在过去的几十年里，肥胖的药物治疗经历了许多变化；不同的药物已经获得批准，新的选择倾向于更高的疗效和更有利的安全性；然而，批准了较长时间的药物仍然可用，对许多患者有用。本文件是巴西肥胖和代谢综合征研究协会（Abeso）和巴西内分泌与代谢学会（SBEM）专家的2024年更新立场声明，目的是审查巴西所有已批准的肥胖治疗药物（西布曲明、奥利司他、利拉鲁肽、西马鲁肽和安非他酮/纳曲酮固定剂量），以及替西帕肽。这种药物已经在其他国家获得批准，可能很快也会在巴西获得批准。这篇综述的重点是疗效、安全性和药物对不同合并症的影响（基于现有研究）。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Archives of Endocrinology Metabolism Medicine-Endocrinology, Diabetes and Metabolism

CiteScore

2.90

自引率

5.90%

发文量

107

审稿时长

7 weeks

期刊介绍： The Archives of Endocrinology and Metabolism - AE&M – is the official journal of the Brazilian Society of Endocrinology and Metabolism - SBEM, which is affiliated with the Brazilian Medical Association. Edited since 1951, the AE&M aims at publishing articles on scientific themes in the basic translational and clinical area of Endocrinology and Metabolism. The printed version AE&M is published in 6 issues/year. The full electronic issue is open access in the SciELO - Scientific Electronic Library Online e at the AE&M site: www.aem-sbem.com. From volume 59 on, the name was changed to Archives of Endocrinology and Metabolism, and it became mandatory for manuscripts to be submitted in English for the online issue. However, for the printed issue it is still optional for the articles to be sent in English or Portuguese. The journal is published six times a year, with one issue every two months.